Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant
chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for
locally advanced esophageal squamous cell cancer (ESCC). However, only 20% to 40% of patients
can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable prognosis
and about 10% of patients have disease progression after chemoradiotherapy. How to improve
the the efficacy of neoadjuvant therapy is an important clinical problem to be solved.
Immunotherapy targeting the programmed cell death receptor-1（PD-1） /programmed cell
death-Ligand 1(PD-L1) checkpoints has demonstrated promising activity in ESCC. In Keynote181
study, for patients with metastatic esophageal squamous cell carcinoma, regardless of PD-L1
expression, pembrolizumab significantly improved overall survival compared with chemotherapy.
However, the efficacy and safety of immunotherapy therapy in surgery-based multidisciplinary
treatment of local advanced esophageal cancer still need a lot of clinical studies to further
confirm.
This study aims to investigate the safety and efficacy of Toripalimab combined with
radiotherapy and chemotherapy in neoadjuvant treatment of locally advanced esophageal
squamous cell carcinoma